Clinical outcomes
A percentage describes a proportion in the stated group. A risk ratio compares two risks: 1 means equal risks and 2 means twice the risk in the specified comparison. Association alone does not establish causation.
EVIDENCE · SOURCE AND ATTRIBUTION
Inspect research governed by microscopIA and work developed in collaboration. Follow each record to its source and scientific context.
A selection of microscopIA research, not the complete portfolio. Some governed projects are not displayed because of nondisclosure agreements or information-protection measures before publication.
Interpret findings alongside the study design, population and limitations. Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Curation and scientific governance →A percentage describes a proportion in the stated group. A risk ratio compares two risks: 1 means equal risks and 2 means twice the risk in the specified comparison. Association alone does not establish causation.
The estimated number of people treated for one additional benefit over a specified period and comparator. It depends on baseline risk and uncertainty.
Methods source ↗A quality-adjusted life-year (QALY) combines length and quality of life. Net monetary benefit values health gains at the stated threshold, then subtracts costs. A cost-effectiveness probability describes model uncertainty, not the probability that a patient improves.
Methods source ↗Read group order, units, design and follow-up with each estimate. Consult the source for confidence intervals and limitations.
Pediatric trauma and reconstructive surgery
This case report describes the staged orthoplastic reconstruction of an 8-cm open Achilles tendon defect following crush trauma in a 7-year-old child, focusing on the reconstructive strategy used to restore tendon continuity and soft-tissue coverage after severe injury.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Record reviewed
Retinopathy of prematurity and health economics
This study evaluates the cost-effectiveness of topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity using multicenter real-world clinical and economic data from Colombia.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →48 ketorolac, 98 nepafenac and 46 historical surveillance comparators.
Record reviewed
Retinopathy of prematurity
This study evaluates real-world clinical outcomes associated with topical ketorolac and nepafenac prophylaxis for early-stage retinopathy of prematurity across a multicenter care network in Colombia.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →48 ketorolac, 98 nepafenac and 46 historical surveillance comparators.
Observational estimate, not a randomized efficacy result.
This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.
Record reviewed
Transplantation and health-system access
This study evaluates graft-specific geographic accessibility to transplant-capable services across Colombia and identifies populations living beyond clinically relevant travel-time thresholds to support transplant-network planning and identify underserved areas.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Record reviewed
Retinopathy of prematurity and health economics
This study compares the cost-effectiveness of bevacizumab and ranibizumab for treatment-requiring retinopathy of prematurity using multicenter real-world clinical and economic data.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Observed retreatment after bevacizumab and ranibizumab, respectively.
Incremental net value favoring bevacizumab at the study threshold.
Share of probabilistic simulations favoring bevacizumab.
This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.
Record reviewed
Critical care access and health-system planning
Principal investigators: Dr. Joseph L. Nates · Dr. Agamenón Quintero Villarreal · Jorge Racedo
This study evaluates population-level travel-time access to intensive-care services across Colombia and identifies areas with prolonged geographic access to inform critical-care policy, service planning, and network design.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.
Record reviewed
Retinopathy of prematurity workforce and access
This study characterizes the distribution of the retinopathy of prematurity workforce in Colombia, evaluates geographic accessibility to care, and examines emerging practice patterns to identify gaps relevant to national service planning.
Public reference available
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →This is a selected list. The linked publication contains the complete, authoritative author and affiliation list.
Record reviewed
Obstetric critical care
Principal investigators: Dr. Joseph L. Nates · Jorge Racedo
A systematic review of 41 reports evaluating prognostic instruments in obstetric intensive or high-dependency care by intended use, target outcome, validation stage, discrimination, calibration, risk of bias and clinical readiness. Evidence supports risk stratification more strongly than transportable individual risk prediction; no universally transportable stand-alone instrument for high-stakes decisions is established.
Full text is not publicly available here.
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Record reviewed
Obstetric critical care
Principal investigators: Dr. Francisco Camargo-Assis
This study evaluates rural–urban differences in obstetric intensive-care admission, organ support, resource use, and maternal–fetal outcomes within a Colombian hospital cohort from 2014 through 2018.
Full text is not publicly available here.
Interpret findings alongside the study design, population and limitations.
Submission or review does not mean acceptance. Preprints have not completed journal peer review.
Report a record correction →Record reviewed
Health economics and decision science
This methodological study evaluates the empirical stability of the incremental cost-effectiveness ratio relative to net monetary benefit under probabilistic uncertainty, examining which metric communicates decision uncertainty more reliably.
Full text is not publicly available here.
Interpret findings alongside the study design, population and limitations.
Report a record correction →Record reviewed
PUBLISHED BOOK CHAPTERS · CRITICAL CARE
Five chapters on electrolyte disorders in oncologic critical care. Explore the first-edition and updated publisher records.
Five chapter topics connect the first edition (online in 2019; book ©2020) with updated 2026 entries. Each edition has its own authors and affiliations; the 2026 microscopIA affiliation is not applied retrospectively. These links show the publishing history, rather than ten distinct research projects.
Published microscopIA affiliation: Department of Health Systems Engineering and Global Health, microscopIA, Bogotá, Colombia.
A published Springer contribution on electrolyte disorders in critically ill patients with cancer. Each chapter is linked to its publisher record and shown here as scholarly output—not as a standalone clinical recommendation.
Oncologic Critical Care · ©2020 ↗Springer Nature · 2026
Springer Nature · 2026
Springer Nature · 2026
Springer Nature · 2026
Springer Nature · 2026
Read the study aim, design and scope before interpreting its findings.
Distinguish scientific governance, collaboration and independent member work.
Check the publication stage, verification date and limits of what was verified.
“Governed” identifies research under microscopIA scientific responsibility and approval processes. “Collaboration” identifies shared work. Neither label changes the publication stage or the limits of the source.
Explore public professional profiles and membership pathways. Contributions and responsibilities are defined for each project.
YOUR NEXT STEP WITH MICROSCOPIA
Read the question, study design, geography and stated relationship. Open the public source and inspect the recorded publication stage.
A microscopIA-governed project and a documented collaboration remain separately attributed. Source verification does not establish a clinical recommendation.
